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Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is one of the most common pathologies of the respira-
tory system. This disease ranks third in the group of the main causes of death in the world. The effective treatment of 
COPD has been developed by today. However, a significant part of physicians has an insufficient amount of education 
in this matter.
Materials and methods: The article represents the results of anonymous prospective survey within the ASCO project 
(full title – “Assessment of Senior Medical Students in the Field of COPD”), aimed at assessing the basic knowledge 
in the COPD treatment. The survey involved 321 physicians and 221 senior medical students from ten cities of Russia 
and Ukraine.
Results and discussion: According to the survey, the following levels of correct answers were given by the doctors 
and students: possible fixed combinations of β2-agonist – 33.9% and 24.5%; the optimal delivery device for a patient – 
50.8% and 41.8; the correct drugs for COPD initial therapy with a high risk of exacerbations – 31.7% and 15.3%, and 
with a low risk – 54.9% and 25.9%, respectively. The correct drugs for COPD aggravation were selected by 43.3% of 
doctors and 34.5% of students; the right empirical treatment of COPD infectious exacerbation – by 72.4% and 40%, 
and the correct reserve drugs – by 63.9% and 36.2%, respectively.
Copyright Bontsevich RA et al. This is an open access article distributed under the terms of  the Creative Commons Attribution License (CC-BY 4.0), which per-
mits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Conclusion: The survey showed that the respondents had medium level of knowledge in COPD treatment. Hence, 
curricula need to be adjusted in medical universities, and additional educational activities are required for medical 
practitioners in order to improve the quality of their knowledge in this field.
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Introduction
Chronic obstructive pulmonary disease is a challenging 
problem, which has been relevant for years (Petty 2006). 
This is due to the constant impact of the main risk factors 
on the human body – smoking, working in hazardous in-
dustries and inhalation of harmful aerosols in cities with an 
increased level of air pollution (Lopez et al. 2006, Murray 
and Lopez 1997, Pauwels and Rabe 2004, WHO 2002).
In 2016, there were 251 million cases of COPD in the 
world (WHO 2017). This pathology ranks third in the 
structure of the main causes of death, 4.8% of the total 
number of causes in the world. In Russia, this disease in-
cidence is 2–11% (Chuchalin 2017). Moreover, COPD is 
one of the main diseases leading to the disability of pa-
tients within a short time (Chuchalin 2017, GOLD 2018).
COPD, as one of the leading pathologies in the modern 
structure of mortality, requires rational treatment aimed 
at targeting the main components of pathogenesis, at pre-
venting and treating complications, at reducing rates of 
disease progression, as well as at improving the quality 
of life of an individual patient (Pauwels and Rabe 2004). 
However, these measures can be taken only by doctors 
with a high level of education in the matters of rational 
therapy of this pathology (de Queiroz et al. 2014, Gökta-
lay et al. 2015, Yawn and Wollan 2008).
The aim of the study: to assess the level of senior 
medical students’ and general physicians’ basic knowl-
edge in COPD treatment by using the method of anony-
mous questioning.
Materials and methods
The doctors and students were surveyed within the ASCO 
project. The first stage of the project was carried out in 2015–
16, the second – ASCO-II – was launched at the end of 2017. 
To date, the results of questionnaires completed by doctors 
were collected and analyzed for nine centers: Krasnodar, Sa-
ratov, Belgorod, Chelyabinsk, Smolensk, Moscow, Lipetsk, 
Voronezh and Vladivostok. The study was also conducted 
among senior students at Belgorod State National Research 
University (Belgorod, Russia), Voronezh State Medical 
University named after N.N. Burdenko (Voronezh, Russia), 
Kuban State Medical University (Krasnodar, Russia), South 
Ural State Medical University (Chelyabinsk, Russia), and 
Dnipropetrovsk State Medical Academy (Dnipro, Ukraine).
The method of anonymous questioning was used in 
this study, for which an original questionnaire was de-
veloped on the basis of current clinical recommendations 
(GOLD 2014, GOLD 2017). The validation of the drafts 
and the final version of the questionnaire was performed 
among the co-authors of the paper and pilot groups of stu-
dents in the regions.
The physicians were asked to specify their specialty, 
category and years of service in their specialty, indicat-
ing whether s/he is taking the questionnaire for the first 
or the second time. The students were required to specify 
their year of studies and major. The respondents did not 
indicate their last names in order to obtain more inde-
pendent results.
The questions concerning the therapy for COPD are pre-
sented below (they are given without variants of answers):
1. Determine the combination of β2-agonist in one addi-
tional device with the proposed groups of drugs.
2. Identify the optimal delivery device for a patient with 
poor coordination and low inspiratory flow rate (<30 
liters per minute).
3. Choose drugs for the initial treatment of COPD with 
advanced symptoms and a high risk of exacerbations.
4. Identify drugs for the basic treatment of COPD with 
advanced symptoms and a low risk of exacerbations.
5. Define drugs used in case of moderate severity COPD 
exacerbation.
6. Specify the drugs of choice for empirical antibiotic 
treatment of infectious exacerbation of COPD.
7. Choose the reserve drugs in case of inefficient antibiot-
ic treatment of infectious exacerbation of COPD.
The respondent was awarded 1 point for each correct 
answer, from 0.25 to 0.75 – for an incomplete answer, 
depending on the completeness of the answer and 0 points 
for the wrong answer. Thus, with all correct answers, the 
maximum average score was 1.0.
The following averages were assessed in the study: the 
average score of each respondent, the average for indi-
vidual questions, the average score  for the centers (cities) 
and the average score for the entire questionnaire. All the 
information entered into the questionnaires was then en-
tered to an electronic database and processed using Mi-
crosoft Excel applications. Statistical data were processed 
through the analysis of arbitrary contingency tables using 
the Pearson’s chi-square (x2) test.
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It is necessary to emphasize that this method of knowl-
edge evaluation is relative, it was specially developed for 
this study, and cannot fully reflect the general level of 
doctors’ knowledge.
In part, the current results of the study were presented 
at the Congresses of the European Respiratory Society 
(2017), the Asia-Pacific Respiratory Society (2015) and 
published in the corresponding conference proceedings 
(Bontsevich et al. 2015, Bontsevich et al. 2017); the re-
sults of the first part of the ASCO study (knowledge of 
senior students) were published in Pharmateca Journal 
(Bontsevich et al. 2018a), some intermediate results of 
the second stage (ASCO-II), concerning the assessment 
of the knowledge of doctors, were published in Vrach 
[Doctor] Journal (Bontsevich et al. 2018b).
Results and discussion
Three hundred and twenty-one physicians were surveyed 
during the study in ten Russian cities (25% were from Bel-
gorod, 18% – from Krasnodar, 17% – from Moscow, 11% 
– from Lipetsk, 9% – from Voronezh, 7% – from Chelya-
binsk, 6 % – from Saratov, 5% – from Smolensk, and 2% – 
from Vladivostok). Two hundred and twenty-one students 
in their fifth and sixth years in medical institutes from five 
cities of Russia and Ukraine were surveyed (50% – from 
Belgorod, 29% – Voronezh, 13% – Dnipro, 5% – Chely-
abinsk, and 3% – Krasnodar). Before the survey, all the 
students had been trained in the standard educational dis-
ciplines – “Therapy” and “Clinical Pharmacology”.
COPD treatment is based on the administration of var-
ious drug combinations depending on a patient’s pheno-
type. At present, there are multiple fixed dosage forms of 
medications containing a combination of groups of drugs: 
short-acting β2-agonists (SABA) and m-anticholinergic 
drugs (MA); long-acting β2-agonists (LABA) and in-
haled glucocorticosteroids (ICS), LABA and long-acting 
MA (LAMA).
The first question required the respondents to identify 
a possible combination of a β2-agonist in the same deliv-
ery device with different groups of drugs (GOLD 2017). 
So, the right answer was given by 33.9% of doctors and 
24.5% of students (p>0.05), who correctly chose ICS and 
m-anticholinergic as the second component of the combi-
nation. The incorrect and partially incorrect answers were 
given by 66.1% of doctors and 55.9% of students, which 
indicates a low level of the respondents’ awareness of 
combination therapy for COPD. The wrong answers were 
distributed as follows: the same number of doctors chose 
only one group of drugs – m-anticholinergic or ICS – 
42.7% and 43.6%, respectively, while 3.8% of the doctors 
chose methylxanthine. The majority of students (61.8%) 
believed that the only right combination was β2-agonist 
with ICS (Fig.1).
The main method of drug delivery to patients suffering 
from COPD is inhalation. The choice of an inhalation de-
vice is based on two main criteria – the inspiratory flow 
rate and the patient’s ability to use the inhaler correctly. 
So, patients with poor coordination or with a low inspira-
tory rate (<30 liters per minute) are recommended to use 
a respimat or nebulizer inhaler (GOLD 2017, Chuchalin 
2017). The correct answer was given by 50.8% of sur-
veyed doctors and 41.8% of students (p>0.05). Most re-
spondents preferred the metered dose inhaler or nebulizer 
– 61.7% of doctors and 64.2% of students, respectively. 
Only 16.6% and 18.4% of respondents chose a dry pow-
der inhaler or nebulizer, respectively (Fig. 2).
The next two questions were related to the basic COPD 
treatment. The treatment of this pathology is known to be 
Figure 1. The structure of the incorrect answers to the question about the combination of β2-agonist in one additional device with 
the proposed groups of drugs.
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based on the choice of an optimal drug or a combination 
of drugs, taking into account the severity of symptoms 
(“COPD Assessment Test” (CAT) and “modified Medical 
Research Council” (mMRC) dispnea scores) and risk of 
exacerbations. The recommendations are made for several 
groups of patients. Drugs administration is recommended 
in accordance with the following clinical types: type A 
implies the initial prescription of bronchodilator for con-
venience and as selected by a doctor and a patient, type 
B – LAMA or LABA, type C – LAMA, type D – LAMA 
+ LABA (Fig. 3) (GOLD 2017, Karloh et al. 2016, Mirza 
et al. 2018, Press et al. 2017).
Until recently, there has been only a combination of 
LABA with ICS (for example, formoterol + budesonide) 
to be used as long-acting drugs. To date, more efficient 
and safe combinations of LABA + LAMA (for example, 
olodoterol + tiotropium) are available. In the near future, 
triple fixed combinations are expected to enter the mar-
ket (LABA + LAMA + ICS), which will be relevant for 
some clinical groups of patients (those with a severe di-
sease course, frequent exacerbations or with eosinophilic 
inflammation) (GOLD 2018, Mirza et al. 2018).
The respondents were required to choose both the in-
itial therapy for a COPD patient with advanced symp-
toms and a high risk of exacerbations (clinical type D) 
and the basic therapy for a COPD patient with advanced 
symptoms and a low risk of exacerbations (clinical 
type B) (GOLD 2017). The first question was correct-
ly answered, by selecting a combination of LAMA and 
LABA, by 31.7% of doctors and by only 15.3% of stu-
dents (p<0.001). The second question was correctly an-
swered – “long-acting m-anticholinergic or β2-agonist, 
or a combination of them for a long time” – by 54.9% 
and 25.9% of doctors and students (p<0.001), respec-
tively. The structure of the incorrect answers to these 
questions is presented in Fig. 4 and Fig. 5. Most often, 
when answering the first question about basic therapy, 
the respondents indicated the option “ICS + LABA” – 
83.1% in the group of doctors and 73.9% in the group of 
students, when answering the second question – 36.1% 
of doctors and 53.3% of students considered that the 
correct answer was “short-acting m-anticholinergic, 
or β2-agonist, or a combination of them according to 
need.”A significant part of the respondents also chose 
the answer “ICS + β2-agonist for a long time” – 36.1% 
and 31.7%, respectively.
The next set of questions concerned the treatment of 
COPD exacerbations. When answering them, 43.3% of 
therapists and 34.5% of students (p>0.05) correctly iden-
tifiied the drugs for moderate exacerbations of COPD 
(short-acting β2-agonist + antimicrobial drug and/or sys-
temic glucocorticosteroid). The most common incorrect 
answer was a combination of β2-agonist with methylxan-
thine, an antimicrobial drug and a systemic corticosteroid 
(49.7% of doctors and 43.1% of students). A short-range 
anticholinergic ± β2-agonist was selected by 20.4% and 
26.7% of respondents, respectively, another 14.4% and 
24.1% considered the correct answer to be ”methylxan-
thine + systemic corticosteroids + mucolytic” (GOLD 
2017, Russian Respiratory Society 2018). The remaining 
15.5% of doctors and 6% of students failed to answer 
this question.
COPD exacerbations are caused by various factors, the 
main of which is bacterial colonization of the respirato-
ry tract. Such exacerbations require an administration of 
antibiotic therapy based on the most common infectious 
agents (pneumococcus, hemophilus, moraxella, etc.). 
The majority of doctors (72.4%) and 40% of students 
(p<0.001) gave the correct answer to the question about 
the empirical treatment of an infectious exacerbation 
of COPD, indicating “amoxicillin / clavulanate, mac-
rolide, or doxycycline” (Chuchalin 2017, GOLD 2014, 
Figure 2. The structure of the incorrect answers to the question about the delivery device.
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GOLD 2017, Russian Respiratory Society 2018). Tak-
ing into account the local resistance of microorganisms 
across the regions, aminopenicillin with beta-lactamase 
inhibitor remains the only one relevant medication for 
the initial COPD therapy. The most common erroneous 
answer – prescribing 2d-3d-gen cephalosporin or doxy-
Figure 3. Patient classification and treatment based on integral assessment of symptoms, spirometric classification and risk of ex-
acerbations for individual treatment recommendations (GOLD 2017, Time of care 2019). Note: LABA – long-acting β2-agonists, 
LAMA – long-acting m-anticholinergic drugs, ICS – inhaled glucocorticosteroids, FEV1 – forced expiratory volume in 1 second, 
CAT – COPD Assessment Test, mMRC – modified Medical Research Council.
Figure 4. The structure of incorrect answers to the question about the initial therapy for a COPD patient with advanced symptoms 
and high risk of exacerbations.
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cycline – was given by 55.6% of physicians and 60.7% 
of students. The significant part of respondents found it 
difficult to answer this question – 18.2% of doctors and 
4.5% of students (Fig.6).
In the last question, the respondents were to identify a 
reserve drug when an infectious exacerbation proved the 
antibiotic therapy ineffective. The correct answer – res-
piratory fluoroquinolones (GOLD 2017, Russian Respira-
tory Society 2018): moxifloxacin and levofloxacin – was 
selected by 63.9% of doctors and 36.2% of students (p 
<0.001). The most common erroneous option among the 
doctors was “cefotaxime or ceftriaxone parenterally” 
– 50%. The erroneous answers in the group of students 
were the following: 33.6% – “cefotaxime or ceftriaxone 
parenteral”, 24.8% – “amoxicillin / clavulanate, clarithro-
mycin”, and 34.5% of students chose the option “cipro-
floxacin, amikacin” (Fig.7).
Conclusions
The survey revealed an average and, in some cases, even 
low level of knowledge of rational therapy for COPD 
among medical majors and physicians (Fig. 8). The most 
Figure 5. The structure of incorrect answers to the question about the basic treatment of COPD in a patient with advanved symptoms 
and low risk of exacerbations.
Figure 6. The structure of the incorrect answers to the question about the empirical antibiotic therapy for a COPD infectious exacerbation.
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difficult were the questions about COPD initial therapy 
and treatment of exacerbations. A lower level of students’ 
knowledge in this area may be due to lack of their practi-
cal experience. However, all the students who answered 
the questionnaire had been recently trained in standard 
educational disciplines of therapy, pulmonology and cli-
nical pharmacology and, in the view of the authors of the 
project, were expected to cope well with COPD basics 
and be aware of modern clinical guidelines. Thus, it can 
be assumed that there is either poor understanding and/
or poor teaching of this topic in medical universities of 
Russia and Ukraine.
Since COPD is a wide-spread disease and has high 
progression rates often causing death and disability of 
people, it is necessary to take extra measures aimed at im-
proving the educational level of physicians and students 
in the treatment of COPD.
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Figure 7. The structure of the incorrect answers to the question about the treatment of COPD infectious exacerbations with the 
inefficiency of the initial antibiotic therapy.
Figure 8. Distribution of correct answers to all questions of the questionnaire among doctors and senior medical students.
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